| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-12-04 | Rodos BioTarget (Germany) | undisclosed | grant | Federal Ministry of Economics and Technology (Germany) | Infectious diseases | Grant |
| 2013-12-02 | Telormedix (Switzerland) | CHF 6 million (€ 4.87 million) | series B financing round | Aravis Venture (Switzerland), Proquest Investments (USA) | Cancer - Oncology - Inflammatory diseases | Series B financing round |
| 2013-11-27 | Bioaxial (France) | € 1.9 million | equity investment | CEA Investissement (France), Inserm Transfert Initiative (France), | Medical devices | Fundraising |
| 2013-11-26 | Bioxodes (Belgium) | € 2.6 million | seed financing round | business angels, European Regional Development Fund (ERDF), Walloon Region via the Retech program for Research and Technology (Belgium) | Series A financing round | |
| 2013-11-25 | Prosensa (The Netherlands) Newcastle University (UK) | € 6 million | grant | European Commission’s Seventh Framework Program (FP7) | Rare diseases - Neuromuscular diseases | Grant |
| 2013-11-21 | Eloxx Pharmaceuticals (Israel) | seed financing | Pontifax (Israel), Roche (Switzerland) | Rare diseases - Genetic diseases | Fundraising | |
| 2013-11-20 | Innate Pharma (France) | € 20.3 million | capital increase | US-based specialist institutional investors including QVT Financial, Redmile Groupe and Orbimed | Cancer - Oncology - Autoimmune diseases | Capital increase |
| 2013-11-20 | Tigenix (Belgium) | € 12 million | private placement | Gri-Cel (Spain) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Private placement |
| 2013-11-20 | Pulmocide (UK) | £17million (€20.4 million) | financing round | Imperial Innovations Group (UK), SV Life Sciences (UK - USA), Fidelity Biosciences (USA), Johnson & Johnson Development Corporation (JJDC) (USA) | Infectious diseases -Respiratory diseases | Fundraising |
| 2013-11-19 | Oxford BioMedica (UK) | £5 million (€ 5.95 million) | loan | Vulpes Life Sciences Fund (Singapore) | Rare diseases - Genetic diseases - Ophtalmological diseases | Loan |
| 2013-11-18 | Cytos Biotechnology (Switzerland) | CHF 24.3 million (€19.7 million) | share placement | Abingworth (UK), venBio (USA), Aisling Capital (USA), Amgen (USA) | Allergic diseases - Immunological diseases | Private placement |
| 2013-11-18 | Mission Therapeutics (UK) | £ 20 million (€ 23.9 million) | series B financing round | Imperial Innovations (UK), Pfizer Venture Investments (USA), Sofinnova Partners (France), SR One (UK), Roche Venture Fund (Switzerland) | Cancer - Oncology | Series B financing round |
| 2013-11-18 | Ganymed Pharmaceuticals (Germany) | € 45 Million | Series E financing round | ATS Beteiligungsverwaltung GmbH (Germany), MIG Fond (Germany), FCPB Gany GmbH (Germany) | Cancer - Oncology | Fundraising |
| 2013-11-14 | DBV Technologies (France) | €29,9 million | private placement | Allergic diseases - Immunological diseases | Private placement | |
| 2013-11-13 | Antabio (France) | € 742,000 | Bpifrance (France) | Infectious diseases | Fundraising | |
| 2013-11-05 | Midatech (UK) | £10 Million (€11.9 million) | Ippon Capital (Switzerland) | Cancer - Oncology - Metabolic diseases | Fundraising | |
| 2013-11-05 | Bionor Pharma (Norway) | NOK 20.6 million (€ 2.26 million) | capital increase | Infectious diseases | Capital increase | |
| 2013-11-04 | MiRacle Consortium [InteRNA Technologies (The Netherlands), VU University Medical Center (The Netherlands), Quiet Therapeutics (Israel), Octoplus, subsidiary of Dr. Reddy’s Laboratories(The Netherlands) LPT (Germany) BioSpring (Germany)] | € 1.2 Million | grant | European Commission’s Seventh Framework Program (FP7) | Cancer - Oncology | Grant |
| 2013-11-04 | Hookipa Biotech (Austria) | €20 million | series B financing round | BioMedPartners (Switzerland), Boehringer Ingelheim Venture Fund (Germany), Forbion Capital Partners (The Netherlands), Sofinnova Partners (France), Takeda Ventures (Japan) | Cancer - Oncology - Infectious diseases | Series B financing round |
| 2013-11-04 | Edmond de Rothschild Investment Partners (France) | €192 million | Edmond de Rothschild Group (France), BPI France (France), insurance companies, retirement funds, public pension funds, social institution, other institutional investors | Establishment of a new subsidiary in the EU |
